Objective: Since peritoneal dialysis causes peritoneal fibrosis, we examined how glucose (osmotic factor), mannitol (osmotic control), and angiotensin II (AngII) regulate proinflammatory cyclooxygenase 2 (COX-2) in primary rat peritoneal mesothelial cells. Materials and Methods: For this study, we used the following material (n = 4-8 cell lines): cells, passages 1-2; 125I-AngII receptor surface binding (AT1R antagonist losartan, AT2R antagonist PD123319; both 10 µM); intracellular calcium probe calcium-5; COX-2 immunoblotting (ß-actin normalized); real-time PCR of COX-2 gene PTGS2, and NF-κB inhibitor Ro-1069920 (5 µM). Results: AngII surface receptors were predominantly AT1R (minimally AT2R). AngII and glucose increased COX-2 protein expression concentration dependently; mannitol also increased COX-2 expression. Maximal COX-2 protein expression was observed after 6 h (AngII) and 24 h (glucose, mannitol). The time course of increases in PTGS2 mRNA levels reflected that of COX-2 protein expression. At optimal exposure conditions (time/concentration), glucose was 5-fold more efficacious in stimulating COX-2 protein expression than AngII or mannitol. Losartan fully inhibited COX-2 protein responses to AngII and mannitol, but minimally inhibited responses to glucose. Ro-1069920 fully inhibited COX-2 protein responses to each effector. Conclusion: AngII, glucose, and osmotic stress (mannitol) activate COX-2; NF-κB may be an ideal site for COX-2 blockade, and COX-2 activation by osmotic stress requires AT1R, but activation by glucose is more robust and mechanistically complex.

Noh H, Ha H, Yu MR, Kim YO, Kim JH, Lee HB: Angiotensin II mediates high glucose-induced TGF-β1 and fibronectin upregulation in HPMC through reactive oxygen species. Perit Dial Int 2005;25:38-47.
Kyuden Y, Ito T, Masaki T, Yorioka N, Kohno N: TGF-β1 induced by high glucose is controlled by angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker on cultured human peritoneal mesothelial cells. Perit Dial Int 2005;25:483-491.
Kiribayashi K, Masaki T, Naito T, Ogawa T, Ito T, Noriaki Y, Kohno N: Angiotensin II induces fibronectin expression in human peritoneal mesothelial cells via ERK1/2 and p38 MAPK. Kidney Int 2005;67:1126-1135.
Duman S, Gunal AI, Sen S, Asci G, Ozkahya M, Terzioglu E, Akcicek F, Atabay G: Does enalapril prevent peritoneal fibrosis induced by hypertonic (3.86%) peritoneal dialysis solution? Perit Dial Int 2001;21:219-224.
Sawada T, Ishii Y, Tojimbara T, Nakajima I, Fuchinoue S, Teraoka S: The ACE inhibitor quinapril ameliorates peritoneal fibrosis in an encapsulating peritoneal sclerosis model in mice. Pharmacol Res 2002;46:505-510.
Coronel F, Berni A, Cigarran S, Calvo N, Herrero JA: Effects of angiotensin II receptor blocker irbesartan on peritoneal membrane functions. Adv Perit Dial 2004;20:27-30.
Ersoy R, Celik A, Yilmaz O, Sarioglu S, Sis B, Akan P, Yenicerioglu Y, Ormen M, Camsari T: The effects of irbesartan and spironolactone in prevention of peritoneal fibrosis in rats. Perit Dial Int 2007;27:424-431.
Nakamoto H, Imai H, Fukushima R, Ishida Y, Yamanouchi Y, Suzuki H: Role of the renin-angiotensin system in the pathogenesis of peritoneal fibrosis. Perit Dial Int 2008;28:S83-S87.
Yao Q, Qian JQ, Lin XH, Lindholm B: Inhibition of the effect of high glucose on the expression of Smad in human peritoneal mesothelial cells. Int J Artif Organs 2004;27:828-834.
Yao Q, Ayala ER, Qian JQ, Stenvinkel P, Axelsson J, Lindholm B: A combination of a PPAR-γ agonist and an angiotensin II receptor blocker attenuates proinflammatory signaling and stimulates expression of Smad7 in human peritoneal mesothelial cells. Clin Nephrol 2007;68:295-301.
Sitter T, Haslinger B, Mandl S, Fricke H, Held E, Sellamyer A: High glucose increases prostaglandin E2 synthesis in human peritoneal mesothelial cells: role of hyperosmolality. J Am Soc Nephrol 1998;9:2005-2012.
Liu H, Peng YM, Liu F, Li J, Chen X, Liu YH, Zhang H: A selective cyclooxygenase-2 inhibitor decreases transforming growth factor-β1 synthesis and matrix production in human peritoneal mesothelial cells. Cell Biol Int 2007;31:508-515.
Aroeira LS, Lara-Pezzi E, Loueiro J, Aguilera A, Ramirez-Huesca M, Gonzalez-Mateo G, Perez-Lozano ML, Albar-Vizcaino P, Bajo MA, del Peso G, Sanchez-Tomero JA, Jimenez-Heffernan JA, Selgas R, Lopez-Cabrera M: Cyclooxygenase-2 mediates dialysate-induced alterations of the peritoneal membrane. J Am Soc Nephrol 2009;20:582-592.
Tsuruda T, Kato J, Kitamura K, Imamura T, Koiwaya Y, Kangawa K, Komuro I, Yazaki Y, Eto T: Enhanced adrenomedullin production by mechanical stretching in cultured rat cardiomyocytes. Hypertension 2000;35:1210-1214.
Tamura K, Chen YE, Chen Q, Nyui N, Horiuchi M, Takasaki I, Tamura N, Pratt RE, Dzau VJ, Umemura S: Expression of renin-angiotensin system and extracellular matrix genes in cardiovascular cells and its regulation through AT1 receptor. Mol Cell Biochem 2000;212:203-209.
Nguyen HT, Adam RM, Bride SH, Park JM, Peters CA, Freeman MR: Cyclic stretch activates p38SAPK2-, ErbB2-, and AT1-dependent signaling in bladder smooth muscle cells. Am J Physiol 2000;279:C1155-C1167.
Saygili E, Rana OR, Meyer C, Gemein C, Andrzejewski MG, Ludwig A, Weber C, Schotten U, Kruttgen A, Weis J, Schwinger RHG, Mischke K, Rassaf T, Kelm M, Schauerte P: The angiotensin-calcineurin-NFAT pathway mediates stretch-induced upregulation of matrix metalloproteinases-2/-9 in atrial myocytes. Basic Res Cardiol 2009;104:435-448.
Lee EA, Oh JH, Lee HA, Kim SI, Park EW, Park KB, Park MS: Structural and functional alterations of the peritoneum after prolonged exposure to dialysis solutions: role of aminoguanidine. Perit Dial Int 2001;21:245-253.
Zareie M, Tangelder GJ, ter Wee PM, Heking LHP, van Lambalgen AA, Keuning ED, Schadee-Eestermans IL, Schalwijk CG, Beelen RHJ, van den Born J: Beneficial effects of aminoguanidine on peritoneal microcirculation and tissue remodeling in a rat model of PD. Nephrol Dial Transplant 2005;20:2783-2792.
Kuper C, Beck FX, Neuhofer W: NFAT5 contributes to osmolality-indcued MCP-1 expression in mesothelial cells. Mediators Inflamm 2012;2012:503015.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.